42 related articles for article (PubMed ID: 23271787)
1. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Mangia A; Mottola L; Piazzolla V
Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
[TBL] [Abstract][Full Text] [Related]
2. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
[TBL] [Abstract][Full Text] [Related]
3. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
[TBL] [Abstract][Full Text] [Related]
4. Individualisation of antiviral therapy for chronic hepatitis C.
Teoh NC; Farrell GC; Chan HL
J Gastroenterol Hepatol; 2010 Jul; 25(7):1206-16. PubMed ID: 20594246
[TBL] [Abstract][Full Text] [Related]
5. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
6. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Cammà C; Cabibbo G; Bronte F; Enea M; Licata A; Attanasio M; Andriulli A; Craxì A
J Hepatol; 2009 Oct; 51(4):675-81. PubMed ID: 19665247
[TBL] [Abstract][Full Text] [Related]
7. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin.
Parikh M; Singh A; Sood G
J Viral Hepat; 2011 Apr; 18(4):e99-103. PubMed ID: 20950407
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
Neukam K; Mira JA; Gilabert I; Claro E; Vázquez MJ; Cifuentes C; García-Rey S; Merchante N; Almeida C; Macías J; Pineda JA
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1225-32. PubMed ID: 21971821
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
Cooper C
Clin Infect Dis; 2012 Aug; 55(3):418-25. PubMed ID: 22491342
[TBL] [Abstract][Full Text] [Related]
10. [THE USE OF COMBINATION ANTIVIRAL THERAPY IN LIVER CIRRHOSIS HCV ETIOLOGY].
Varlamov V I ; Ivanova AL; Tarasova LV
Eksp Klin Gastroenterol; 2015; (11):92-4. PubMed ID: 27214995
[TBL] [Abstract][Full Text] [Related]
11. Individualization of antiviral treatment regimens for chronic hepatitis C.
Paulon E; Naoumov NV
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.
Kanda T; Matsuoka S; Moriyama M
Hepatol Int; 2018 Jul; 12(4):291-293. PubMed ID: 29992512
[No Abstract] [Full Text] [Related]
13. [Therapeutic behaviour for a HCV+ patient].
Buffet C
Presse Med; 2004 Apr; 33(7):497-8. PubMed ID: 15105775
[No Abstract] [Full Text] [Related]
14. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
Bizollon T; Trepo C
J Hepatol; 2002 Aug; 37(2):274-6. PubMed ID: 12127435
[No Abstract] [Full Text] [Related]
15. You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
Pearlman BL; Lim TH
Dig Dis Sci; 2014 Aug; 59(8):1681-3. PubMed ID: 25002310
[No Abstract] [Full Text] [Related]
16. [Evaluation of tolerance and efficacy of the treatment of chronic viral hepatitis C in homozygous sickle cell patients].
El Agheb MO; Grange JD
Pan Afr Med J; 2015; 20():99. PubMed ID: 26213600
[TBL] [Abstract][Full Text] [Related]
17. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population.
Schwimmer JB; Balistreri WF
Semin Liver Dis; 2000; 20(1):37-46. PubMed ID: 10895430
[TBL] [Abstract][Full Text] [Related]
18. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice.
El-Shabrawi M; Isa M
Hepat Mon; 2013 Feb; 13(2):e7867. PubMed ID: 23610587
[No Abstract] [Full Text] [Related]
19. Hepatitis C in Argentina: epidemiology and treatment.
Gaite LA; Marciano S; Galdame OA; Gadano AC
Hepat Med; 2014; 6():35-43. PubMed ID: 24966701
[TBL] [Abstract][Full Text] [Related]
20. Treatment decisions and contemporary versus pending treatments for hepatitis C.
Trembling PM; Tanwar S; Rosenberg WM; Dusheiko GM
Nat Rev Gastroenterol Hepatol; 2013 Dec; 10(12):713-28. PubMed ID: 24019151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
